Author’s response to reviews

Title: Treatment of aortic thrombosis with retrievable stent filter and thrombolysis: a case report

Authors:

Yonghua Bi (274233911@qq.com)
Hongmei Chen (275547292@qq.com)
Wenguang Zhang (fancyvo@126.com)
Jianzhuang Ren (rrjzzjrk@126.com)
Xinwei Han (dreamweaver08@126.com)

Version: 1 Date: 05 Jan 2019

Author’s response to reviews:

Professor Marzia Cottini
BMC Cardiovascular Disorders

January 5, 2019

Dear Editor and Reviewers,

Thank you for your letter and for the reviewers’ comments concerning our manuscript. We greatly valued all the comments, which were very helpful for us to revise the paper and to improve its quality. Based on your comments, we have made careful revision throughout the manuscript. To the best of our abilities, we modified the manuscript to improve its understandability and scientific quality.

Comments to the Author

Technical Comments:

Editor Comments:

Dear Author,

your manuscript is interesting but it needs some clarifications before publishing.
Please follow the reviewer suggestion and resend the revisioned manuscript.

Regards

BMC Cardiovascular Disorders operates a policy of open peer review, which means that you will be able to see the names of the reviewers who provided the reports via the online peer review system. We encourage you to also view the reports there, via the action links on the left-hand side of the page, to see the names of the reviewers.

Reviewer reports:

Reviewer 1

Yonghua Bi et colleagues presented an interesting and first-reported case report of a retrievable filter stent for treating -together with fibrinolysis- an extensive aortic thrombosis. This case I really interesting and could be valuable for publication, despite some issues should be addressed before it.

-First off, this is an off-label indication, but no mention of consensus from the patient is mentioned.

Answer: Thanks for your comments. Written informed consent was obtained from the patient for the use of retrievable filter stent.

-Second, why the authors used urokinase in spite of other less dangerous fibrinolytic drugs?

Answer: Thanks for your professional question. As you pointed out, the less dangerous fibrinolytic drugs, such as rt-PA can be used for thrombolysis (1)(2).

Since urokinase is significantly cheaper than rt-PA, we usually choose urokinase for thrombolysis rather than rt-PA to reduce the economic burden of patients in this study.

-It is not reported on which medication the patents was discharged. -It is not reported if they discovered the cause, or at least the underlying diagnosis, of the contemporary venous and aortic thrombosis.

Answer: Thanks for your comments. Patients received oral take of warfarin sodium of 100 mg per day for anticoagulation with a international normalized ratio of 2-3 if no contraindications.
Thrombophilia was the underlying diagnosis of the contemporary venous and aortic thrombosis for this patient.

-English language is very poor and should be revised before publication. -the characteristics of the RSF used (and its commercial name) were not reported.

Answer: Thanks for your comments. This manuscript has been edited for proper English language, grammar, punctuation, spelling, and overall style by highly qualified native English speaking professional editors at PaperTalks.org.

Reviewer 2

The authors should be congratulated for describing an interesting case of using retrieval stent filter with thrombolysis for treating aortic thrombosis. My biggest concern with this manuscript is that this is written by non-native english speakers and is difficult to read and comprehend given the extensive grammatical and language errors. These make this manuscript unsuitable for publication in its current form in an English language journal.

Answer: Thanks for your comment. This manuscript was edited by native English speaker.

Reviewer 3

Authors presented the interesting case worth publishing. However, authors should clearly state what was the reason for so massive thrombosis.

Answer: Thanks for your comments. Thrombophilia was the underlying diagnosis of the contemporary venous and aortic thrombosis for this patient. However, this diagnosis was not confirmed. This case report focuses on treatment of aortic thrombosis with RSF. This shortcoming is added in the section of discussion.

If improvements to the English language within your manuscript have been requested, you should have your manuscript reviewed by someone who is fluent in English. If you would like professional help in revising this manuscript, you can use any reputable English language editing service. We can recommend our affiliates Nature Research Editing Service (http://bit.ly/NRES_BS) and American Journal Experts (http://bit.ly/AJE_BS) for help with English usage. Please note that use of an editing service is neither a requirement nor a guarantee of publication. Free assistance is available from our English language tutorial (https://www.springer.com/gb/authors-editors/authorandreviewertutorials/writinginenglish) and our Writing resources (http://www.biomedcentral.com/getpublished/writing-resources). These cover common mistakes that occur when writing in English.
Answer: This manuscript has been edited for proper English language, grammar, punctuation, spelling, and overall style by highly qualified native English speaking professional editors at PaperTalks.org.

----------------------Editorial Policies----------------------

Please read the following information and revise your manuscript as necessary. If your manuscript does not adhere to our editorial requirements, this may cause a delay while this is addressed. Failure to adhere to our policies may result in rejection of your manuscript.

In accordance with BioMed Central editorial policies and formatting guidelines, all manuscript submissions to BMC Cardiovascular Disorders must contain a Declarations section which includes the mandatory sub-sections listed below. Please refer to the journal's Submission Guidelines web page for information regarding the criteria for each sub-section (https://bmccardiovascdisord.biomedcentral.com/).

Where a mandatory Declarations section is not relevant to your study design or article type, please write "Not applicable" in these sections.

For the 'Availability of data and materials' section, please provide information about where the data supporting your findings can be found. We encourage authors to deposit their datasets in publicly available repositories (where available and appropriate), or to be presented within the manuscript and/or additional supporting files. Please note that identifying/confidential patient data should not be shared. Authors who do not wish to share their data must confirm this under this sub-heading and also provide their reasons. For further guidance on how to format this section, please refer to BioMed Central's editorial policies page (see links below).

Declarations

- Ethics approval and consent to participate
- Consent to publish
- Availability of data and materials
- Competing interests
- Funding
- Authors' Contributions
- Acknowledgements

Further information about our editorial policies can be found at the following links:
Ethical approval and consent:

http://www.biomedcentral.com/about/editorialpolicies#Ethics

Availability of data and materials section:

http://www.biomedcentral.com/submissions/editorial-policies#availability+of+data+and+materials

Answer: Thanks for your comments. This error was changed during submission.